The UK’s medicines regulator is investigating whether private clinics are breaking the law by marketing experimental peptide therapies with claims of health benefits that lack scientific backing in humans. The Medicines and Healthcare products Regulatory Agency (MHRA) is scrutinizing these services after a surge in the use of injectable peptides touted for everything from anti-aging and cognitive enhancement to injury recovery.
While some peptides are legitimate, approved medications, a growing number of clinics are offering unregulated versions. The core of the current regulatory conflict lies in how these substances are marketed: if a clinic claims a product can treat or prevent a disease—or modify a physiological function—it is legally classified as a medicine and must be regulated under the Human Medicines Regulations 2012.
The gap between approved medicine and experimental claims
Peptides are short chains of amino acids that occur naturally in the body; insulin, which regulates blood sugar, is a well-known example. In recent years, synthetic peptides that mimic natural hormones have led to the development of approved prescription weight-loss drugs, such as semaglutide (Wegovy) and tirzepatide (Mounjaro).
However, a separate market has emerged for experimental peptides that have not undergone the same rigorous regulatory processing. A Guardian investigation found clinics promoting substances like Cortexin for “cognitive enhancement,” Thymosin Alpha to “boost immune function,” and BPC-157 for “tissue repair.”
The danger is that the evidence supporting these claims is often profoundly limited. In many cases, the research cited by sellers is pre-clinical, meaning the studies were conducted in cells or animals rather than human beings. There is a notable absence of large-scale, randomized multi-centre clinical trials to determine the long-term safety or efficacy of these treatments.
Regulatory Definition: Medicinal Products
According to the MHRA, a medicinal product includes any substance presented as having properties to prevent or treat disease in humans—where “disease” encompasses any injury, ailment, or adverse condition of body or mind. It also includes substances used to restore, correct, or modify a physiological function through pharmacological, immunological, or metabolic action.
The “research only” loophole and patient risk
To avoid the strict oversight of medicines laws, some clinics label their peptides as “research only” while simultaneously advertising them with specific “results durations” and price tags—sometimes costing between £350 and £450 per month. These products are often delivered via vials with disposable syringes or pre-loaded injection pens.
Lynda Scammell, head of borderline products at the MHRA, stated that the agency disregards claims that products are for “research purposes” if it is clear those claims are being used to bypass regulation. If promotional materials show the products are intended for human use, the MHRA will take regulatory action.
Beyond the legalities, We find significant safety concerns. For instance, BPC-157 is frequently recommended for muscle and tissue recovery. However, clinicians have noted that it may not be suitable for individuals who smoke or have a family history of cancer, due to concerns that the peptide could increase blood supply to certain tissues and potentially fuel the growth of cancer.
Another peptide, MOTS-C, is marketed to improve mitochondrial health and reduce visceral fat by increasing ATP production and reducing insulin resistance. Yet, like many in this category, these recommendations are often based on theoretical benefits rather than established human clinical data.
This trend is not isolated to the UK; similar “injectable peptide crazes” have been reported in the US, where critics suggest some individuals are effectively turning themselves into “lab rats” by using substances without clinical oversight.
Clinics have defended their practices by arguing that they use “shared decision-making” and provide balanced information on uncertainties. They also point out that many people are already accessing these products through unregulated online networks and messaging platforms, where there is no quality assurance or safety screening at all.
The MHRA continues to evaluate these products on a case-by-case basis, considering the product’s effect on the body, the method of use, and available legal precedents.
As these experimental therapies become more accessible via social media and private clinics, the divide between evidence-based medicine and high-cost wellness trends continues to widen.
Understanding the Risks
- Lack of Human Data: Most “benefits” are derived from animal or cell studies, not human trials.
- Unforeseen Side Effects: Without long-term studies, the chronic effects of these peptides remain unknown.
- Specific Contraindications: Certain peptides, like BPC-157, may pose risks to people with a history of cancer.
- Regulatory Evasion: “Research only” labels do not guarantee safety or legality when the product is sold for human use.
When considering an experimental treatment, how do you verify if the evidence provided is based on human clinical trials or pre-clinical animal research?
